Pfizer Korea's Plunazol-related claim for damage is unlikely to affect Daewoong Pharm

Published: 2003-10-16 07:00:00

Updated: 2003-10-16 07:00:00

Hanyang Securities Co. said that Pfizer Korea submitted to Seoul District Court its claim for damage against patent infringement of Daewoong Pharm over Plunazol, which annualized domestic sales of 23.8 billion won last year and the third trial to confirm the scope of Pfizer's Plunazol patent righ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK